Insmed Incorporated (INSM) is a Biotechnology company in the Healthcare sector, currently trading at $153.40. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is INSM = $216 (+41.1% upside).
Valuation: INSM trades at a trailing Price-to-Earnings (P/E) of -26.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.19.
Financials: revenue is $606M, +36.8%/yr average growth. Net income is $1.3B (loss), growing at -39.1%/yr. Net profit margin is -210.5% (negative). Gross margin is 79.4% (+1.9 pp trend).
Balance sheet: total debt is $768M against $739M equity (Debt-to-Equity (D/E) ratio 1.04, moderate). Current ratio is 3.83 (strong liquidity). Debt-to-assets is 33.9%. Total assets: $2.3B.
Analyst outlook: 32 / 34 analysts rate INSM as buy (94%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 74/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 72/100 (Pass), Future 100/100 (Pass), Income 10/100 (Fail).
